U.S. patent application number 16/674602 was filed with the patent office on 2020-03-12 for system for analyzing and treating abnormality of human and animal tissues.
The applicant listed for this patent is Truerelief, LLC. Invention is credited to Ronald J. Weinstock.
Application Number | 20200077943 16/674602 |
Document ID | / |
Family ID | 42733966 |
Filed Date | 2020-03-12 |
![](/patent/app/20200077943/US20200077943A1-20200312-D00000.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00001.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00002.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00003.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00004.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00005.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00006.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00007.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00008.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00009.png)
![](/patent/app/20200077943/US20200077943A1-20200312-D00010.png)
View All Diagrams
United States Patent
Application |
20200077943 |
Kind Code |
A1 |
Weinstock; Ronald J. |
March 12, 2020 |
SYSTEM FOR ANALYZING AND TREATING ABNORMALITY OF HUMAN AND ANIMAL
TISSUES
Abstract
A patient treatment unit for analyzing and treating abnormality
of human or animal tissues, includes a display; a pulse generator
circuit that outputs a sequence of electrical pulses at a pulse
frequency, the electrical pulses having a pulse width, the pulse
generator controlling the pulse frequency and the pulse width of
the electrical pulses; a pair of probes for contacting a body of a
patient and electrically coupled to the pulse generator; and a
voltage and current sensing circuit that senses a voltage or a
current via the probes when contacting the body of the patient.
Inventors: |
Weinstock; Ronald J.;
(Corona Del Mar, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Truerelief, LLC |
Santa Monica |
CA |
US |
|
|
Family ID: |
42733966 |
Appl. No.: |
16/674602 |
Filed: |
November 5, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15918779 |
Mar 12, 2018 |
10499848 |
|
|
16674602 |
|
|
|
|
15378357 |
Dec 14, 2016 |
|
|
|
15918779 |
|
|
|
|
14736827 |
Jun 11, 2015 |
9550068 |
|
|
15378357 |
|
|
|
|
14338700 |
Jul 23, 2014 |
9079029 |
|
|
14736827 |
|
|
|
|
13690752 |
Nov 30, 2012 |
8849371 |
|
|
14338700 |
|
|
|
|
13269017 |
Oct 7, 2011 |
8326398 |
|
|
13690752 |
|
|
|
|
12456657 |
Jun 19, 2009 |
8064988 |
|
|
13269017 |
|
|
|
|
10856632 |
May 28, 2004 |
7801585 |
|
|
12456657 |
|
|
|
|
60474843 |
Jun 2, 2003 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61N 2/02 20130101; A61N
5/10 20130101; A61N 2/002 20130101; A61N 2/008 20130101; A61N
2005/1087 20130101; A61B 5/0035 20130101; A61N 1/36021 20130101;
G01R 33/60 20130101; A61N 2005/1091 20130101; A61B 5/742 20130101;
A61B 5/055 20130101; A61B 5/053 20130101; A61B 5/4836 20130101 |
International
Class: |
A61B 5/00 20060101
A61B005/00; A61N 5/10 20060101 A61N005/10; A61N 2/00 20060101
A61N002/00; A61N 1/36 20060101 A61N001/36; A61N 2/02 20060101
A61N002/02; A61B 5/055 20060101 A61B005/055; G01R 33/60 20060101
G01R033/60 |
Claims
1. A patient treatment unit for analyzing and treating abnormality
of human or animal tissues, comprising: a display; a pulse
generator circuit that outputs a sequence of electrical pulses at a
pulse frequency, the electrical pulses having a pulse width, the
pulse generator controlling the pulse frequency and the pulse width
of the electrical pulses; a pair of probes for contacting a body of
a patient and electrically coupled to the pulse generator; and a
voltage and current sensing circuit that senses a voltage or a
current via the probes when contacting the body of the patient.
2. The patient treatment unit of claim 1, further comprising a
circuit for detecting an overvoltage or an overcurrent in the
electrical pulses.
3. The patient treatment unit of claim 1, wherein the electrical
pulses are substantially rectangular pulses when the probes have a
substantially open circuit between them.
4. The patient treatment unit of claim 1, wherein the pulse
frequency is in a range of 1-490 Hz.+-.6% from 500 ohms to 1
mega-ohm of resistance across the probes.
5. The patient treatment unit of claim 1, wherein the pulse width
is not less than 0.34 milliseconds and is not greater than 0.74
milliseconds.
6. The patient treatment unit of claim 1, wherein a peak voltage of
the electrical pulses across the probes when a 500 ohm resistance
is present across the probes does not exceed about 4 volts.
7. The patient treatment unit of claim 1, wherein a peak voltage of
the electrical pulses across the probes when a 5 kilo-ohm
resistance is present across the probes does not exceed about 30
volts.
8. The patient treatment unit of claim 1, wherein a peak voltage of
the electrical pulses across the probes when a 10 kilo-ohm
resistance is present across the probes does not exceed about 40
volts.
9. The patient treatment unit of claim 1, wherein one of the probes
includes a potentiometer for adjusting a characteristic of the
electrical pulses.
10. The patient treatment unit of claim 1, wherein the
characteristic is the pulse frequency.
11. The patient treatment unit of claim 1, wherein the maximum
current output of the pulse generator circuit is not greater than
8.9 milliamps.
12. The patient treatment unit of claim 1, wherein the maximum
charge of electrical pulse does not exceed 7 micro-coulombs.
13. The patient treatment unit of claim 1, wherein the pulse
generator circuit includes current and voltage limiting means.
14. The patient treatment unit of claim 1, further comprising a
microcontroller for controlling the display.
15. A patient treatment unit for analyzing and treating abnormality
of human or animal tissues, comprising: a display controlled by a
microcontroller; a pulse generator circuit including current and
voltage limiting means, the pulse generator circuit outputting a
sequence of electrical pulses at a pulse frequency, the electrical
pulses having a pulse width, the pulse generator controlling the
pulse frequency and the pulse width of the electrical pulses,
wherein the pulse width is not less than 0.34 milliseconds and is
not greater than 0.74 milliseconds, wherein the maximum current
output of the pulse generator circuit is not greater than 8.9
milliamps, wherein the maximum charge of electrical pulse does not
exceed 7 micro-coulombs; a pair of probes for contacting a body of
a patient and electrically coupled to the pulse generator, wherein
the electrical pulses are substantially rectangular pulses when the
probes have a substantially open circuit between them, wherein one
of the probes includes a potentiometer for adjusting a
characteristic of the electrical pulses; a voltage and current
sensing circuit that senses a voltage or a current via the probes
when contacting the body of the patient, wherein a peak voltage of
the electrical pulses across the probes when a 500 ohm resistance
is present across the probes does not exceed about 4 volts; and a
circuit for detecting an overvoltage or an overcurrent in the
electrical pulses.
16. The patient treatment unit of claim 15, wherein the pulse
frequency is in a range of 1-490 Hz.+-.6% from 500 ohms to 1
mega-ohm of resistance across the probes.
17. The patient treatment unit of claim 15, wherein a peak voltage
of the electrical pulses across the probes when a 5 kilo-ohm
resistance is present across the probes does not exceed about 30
volts, and wherein a peak voltage of the electrical pulses across
the probes when a 10 kilo-ohm resistance is present across the
probes does not exceed about 40 volts.
18. The patient treatment unit of claim 15, wherein the
characteristic is the pulse frequency.
19. The patient treatment unit of claim 16, wherein a peak voltage
of the electrical pulses across the probes when a 5 kilo-ohm
resistance is present across the probes does not exceed about 30
volts, and wherein a peak voltage of the electrical pulses across
the probes when a 10 kilo-ohm resistance is present across the
probes does not exceed about 40 volts, and wherein the
characteristic is the pulse frequency.
20. A patient treatment unit for analyzing and treating abnormality
of human or animal tissues, comprising: a display; a
microcontroller for controlling the display; a pulse generator
circuit that outputs a sequence of electrical pulses at a pulse
frequency, the electrical pulses having a pulse width, the pulse
generator controlling the pulse frequency and the pulse width of
the electrical pulses, wherein the pulse generator circuit includes
current and voltage limiting means; a pair of probes for contacting
a body of a patient and electrically coupled to the pulse
generator; a circuit for detecting an overvoltage or an overcurrent
in the electrical pulses; and a voltage and current sensing circuit
that senses a voltage or a current via the probes when contacting
the body of the patient, wherein one of the probes includes a
potentiometer for adjusting the pulse frequency of the electrical
pulses, wherein the maximum current output of the pulse generator
circuit is not greater than 8.9 milliamps.
Description
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No.
10/856,632, filed May 28, 2004, which claims the benefit under 35
USC 119(e) of the provisional patent application Ser. No.
60/474,843, filed Jun. 2, 2003. All prior applications above are
hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
A. Area of Invention
[0002] The present invention relates to electromedicine and, more
particularly, to the application of a magnetic field to tissue and
the subsequent measurement of electron spin and paramagnetic
resonance properties of the tissue to ascertain and treat
abnormalities associated therewith and with specific disease
states.
B. Prior Art
[0003] The value and application of electron magnetic resonance
(EMR) in biomedicine has been recognized, given its similarity, at
least in principle, to proton magnetic resonance (often termed
nuclear magnetic resonance or NMR). However, the field and
frequency conditions under which an EMR signal is seen are
different. In proton MRI, one of most common forms of NMR, the DC
field may be on the order of 20,000 gauss (2 Tesla) at a radio
frequency of about 85 MHz. In new high resolution NMR, the field
strength may be increased to 12 Tesla at a microwave frequency of
about 500 MHz. In distinction, the field associated with an EMR
field may be as low as a fraction of a Tesla and under 1 GHz. These
conditions, which historically related to different
instrumentation, more importantly have lead to the realization that
EMR techniques can be several orders of magnitude more sensitive
than NMR, given that the electron magnetic moment is approximately
650 times stronger than that of the proton, even though the mass of
the electron is far less than that of a proton, as above noted, is
obtainable at field strengths and frequencies that are far less
intrusive and, thereby, less hazardous than those associated with
NMR. Because of these actors, the primary historic use of the NMR
has been in association with analysis, imaging, and diagnosis of a
wide variety of tissue related traditions, while NMR found little
application in the treatment of tissue abnormalities or
disorders.
[0004] EMR was discovered in 1925 by Goudsmit and Uhlenbeck.
Thereafter its practical application was primarily in EMR
spectrometers and, through the present, is used primarily in such
applications. See for example U.S. Pat. No. 6,335,625 (2002) to
Bryant et al.
[0005] EMR, sometimes termed electron paramagnetic resonance (EPR),
has become a generic name given to the magnetic behavior of the
electron when immersed in an external magnetic field. In EMR, the
electron exhibits two key properties, namely, its magnetic field
and a gyroscopic behavior. Therein, its electric field plays no
part. Its magnetic field is often termed its dipole moment while
its gyroscopic behavior is called its gyroscopic moment.
[0006] The greater the time domain differences between the magnetic
components of an electromagnetic wave of a tissue, the greater will
be the phase differences between the components and, thereby, the
greater the energy loss or gain. As such, measurement of
differences in phase between both magnetic moments of the electron
have developed as a means of recognizing differences of properties
between respective materials subject to an EM wave of typically of
dipole and gyroscopic moment inducing strength. This phase change
and energy loss or gain relates exponentially to cellular and
tissue function.
[0007] From the perspective of quantum mechanics, the electron,
while shifting positions within a permissible set of patterns
relative to the atomic nucleus, generates specific energy emissions
or spectra, i.e., EMR by body tissues and physiological structures.
Such patterns have been found to comprise unique tissue signatures
and, as such, a product of the individual atomic, molecular and
cellular quantum movements which characterize the given tissue,
organ or physiological structure of interest. Thereby, from my
perspective of biophysics, the initial step in pathology emanating
from a dysfunctional, damaged or diseased tissue is considered a
misfunction of the EMR of the normal electron cloud associated with
such tissue. EMR disorders thereby predispose biochemical and
bioelectrical alterations reflected in each unique EMR signature of
the tissue or structure of interest. When a disorder of measurable
EMR occurs, the resonance and configuration of the normal electron
cloud at the atomic level exhibit phase shifts which break and
disturbs the otherwise orderly pathways of communication from atom
to molecule, molecule to cell, cell to tissue, and tissue to organ.
This results in breakdown in molecular and cellular communication
one end result for example being a reduction in tissue
conductivity.
[0008] For the inventive electron magnetic resonance analyzer and
treatment system to function, the system sends or receives
information to and from the body, the body's cellular network or in
some cases, the central nervous system, that is, its pain
processing center. This pathway allows the EMR of the inventive
system to record and analyze any phase-shifted EMR patterns
emanating by and from the body's tissues and structures.
[0009] In case of assessing and treating pain, the inventive system
also employs inductors and applicators at the site of pain, tissue
abnormality and/or upon selected nervous system trigger or motor
points (which can also comprise of acupuncture or pressure points).
A synthesized EMR pattern is transmitted into the tissue which
encounters the inherent resonance pattern produced by the tissue or
subject matter under study. The information generated by this
initial step of the analysis process is returned to the system
where, after removal of impedance static in the signal it is
analyzed, digitized and, if desired, compared to predetermined EMR
patterns associated with such normal tissue. Thereby, the recorded
data is assessed and evaluated for irregulates or abnormalities.
The inherent EMR signatures of normal atoms, molecules, tissues and
structures may thereby be employed as "standards" in the digitizing
of values based on recorded and peak resonance emissions of
healthy, non-diseased, non-damaged tissues. When such a first phase
of the EMR pattern measurement and assessment is complete, the
system has detected any disorder or shifting of EMR peaks at the
pain site under study, if a phase shifts exists.
[0010] A second aspect of operation of the inventive system is that
of its therapeutic action. If an EMR phase shift of the targeted
tissue or organ is detected in the first aspect of analysis, the
shift can be corrected through the application of a counter or
neutralizing EMR which, as set forth below, is calculated and
computed by the system, thereby resulting in a neurotransmitter
function which is regulated by administration of a counter EMR
pattern. It has been found that upon realignment of the phase
shifted EMR pattern, reduction and alleviation of pain occur
instantaneously, healing time is reduced and, upon suitable
repetition of therapy, result in long term improvement of the
abnormality of interest.
[0011] Pain is reduced or eliminated by means of effect on
nociceptive afferent neurons which are sensitive to magnetic as
well as a variety of noxious stimuli including thermal, mechanical,
and chemical. Excitation of nociceptive neurons induce a field
gradient into magnetic sensitive ion channels, particularly sodium,
calcium and potassium channels. Nerve terminal membranes are
magnetically encoded through the activation of inward depolarizing
membrane currents or activation of outward currents. The main
channels responsible for inward membrane currents are the voltage
activated sodium and calcium channels.
[0012] It is known that an ionic gradient exists across the plasma
membrane of virtually all human and animal cells. In particular,
the concentration of potassium ions inside the cell is about ten
times that in the extracellular fluid. Also sodium ions are present
in much higher concentrations outside a cell than inside. As such,
the potassium and sodium channels play an important role in
membrane excitation and, thereby, in determining the intensity of
pain. Sodium channels are now considered a destabilizing membrane
in the pain process. These channels, which can open rapidly and
transiently when the membrane is depolarized beyond about minus 40
mV, are essential for action of most neurons, potential generation,
and conduction. These open channels are also believed to be
responsible for the neuron action leading to pain. Sodium is also
an alkali element (with an atomic number of 11) and is
paramagnetic. That is, when placed in a magnetic field, a
paramagnetic substance becomes magnetized parallel to the field. It
is believed that a magnetic interaction thereby occurs between
sodium channels and the EMR patterns and peaks discussed above. EMR
affects sodium which in turn affects the excitability of
nociceptive neurons which are chemically distinct from most other
neurons
[0013] It has been found that EMR fields which consist of an EM
carrier of a range of about 1 Hz to about 1 GHz, when modulated by
EMR patterns in a range of about 0.1 gauss to about 4 Tesla,
provide a regulating effect upon sodium channels, this leading to
pain reduction.
[0014] Tests have also indicated that EMR fields alter the pH level
of water, which relates to another theory of the pain reduction
associated with the present system. That is, it has been shown that
the pH of extra-cellular fluid is associated with a number of
patho-physiological conditions such as hypoxia/anoxia and
inflammation. It has been reported that the pH of synovial fluid
from enflamed joints is significantly more acid than is that of
normal joints. As such, low pH solutions evoke a prolonged
activation of sensory nerves and produce a sharp stinging pain.
Consequently, when pH of tissue is changed, pain reduction is often
achieved.
[0015] Successful treatment of arthritis, fibromyalgia, neuralgia,
neuropathy, categories of joint and tissue injury, wound healing,
calcific tendonitis, and various types of migraine headaches has
been demonstrated.
SUMMARY OF THE INVENTION
[0016] A patient treatment unit for analyzing and treating
abnormality of human or animal tissues, includes a display; a pulse
generator circuit that outputs a sequence of electrical pulses at a
pulse frequency, the electrical pulses having a pulse width, the
pulse generator controlling the pulse frequency and the pulse width
of the electrical pulses; a pair of probes for contacting a body of
a patient and electrically coupled to the pulse generator; and a
voltage and current sensing circuit that senses a voltage or a
current via the probes when contacting the body of the patient.
[0017] It is an object of the present invention to employ
principles of electron magnetic resonance (EMR) for the analysis
and relief of pain and correction of abnormalities of human
tissue.
[0018] It is another object to provide a system to analyze and
digitize normal EMR patterns of specific tissues.
[0019] It is further object of the invention to correct abnormal
EMR patterns by applying a countervailing or neutralizing EMR field
spectra utilizing inductive sensors and applicators to apply EMR
patterns of an intensity from about 0.1 gauss to about 4 Tesla.
[0020] It is further object to measure and analyze EMR out-of-phase
peak resonances associated with abnormal tissue function, chronic
pain, and traumatic injuries of soft tissue.
[0021] It is further object to provide a system of the above type
in which useful. EMR pattern information is measured at a trigger
point, at or near a tissue dysfunction or pain site, and a counter
resonance pattern is applied to said site to realign phase shifted
resonance patterns associated with the electron of cells affection
by an abnormal or pain condition.
[0022] It is further object to provide a system of the above type
which can be readily interfaced with existing electromedical
technologies including, without limitation, CT Scan, MRI,
stereotactic imaging, and PET scanning. The advantage of this
interface is the ability to visually "light up" an anatomical area
with phase shift activity. By using an algorithm to monitor the
amplitude of the signal and the degree of electromagnetic flux
variation, various colors can be assigned to this phenomenon
indicating antiphase or phase shifted areas. i.e., red being a
reactive area and blue being a normal area. This information can
then overlay a two or three dimensional diagnostic image, visually
pinpointing an antiphase or phase shifted anatomical area. The
advantage of this is being able to visualize functional variations
and abnormalities as well as gross anatomical abnormalities.
Another iteration of the technology is the attachment of an LCD
screen to the back of a hand held wireless induction coil.
Anatomical areas of the body can be scanned while watching for
color changes on the attached LCD when a phase shift area is
detected.
[0023] The above and other objects in advantage of the present
invention will become apparent from the hereinafter set forth.
Brief Description of the Drawings, Detailed Description of the
Invention and Claims appended herewith.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 is a block diagram showing the basic hardware and
software functions of the inventive system.
[0025] FIG. 2 is a schematic view of a patient treatment unit
("PTU") and associated diagnostic unit.
[0026] FIG. 3 is a block diagram view of a functional management
unit ("FMU").
[0027] FIG. 4 is a block diagram view of the local controller and
system custom software operating upon a PC platform to control the
PTU and manage a patient list. Also shown is a radio interface unit
between the PC and the PTU.
[0028] FIG. 5 is a block diagram view of a tissue measurement
module.
[0029] FIGS. 5A-5D show impedance, power and frequency
relationships for the PTU.
[0030] FIG. 6 is a block diagram view of a communication
module.
[0031] FIG. 7 is a block diagram view of the PTU inclusive of the
PC radio interface and local controls of the PTU.
[0032] FIG. 8 is a block diagram view of the stimuli module.
[0033] FIGS. 9 and 10 are a respective signal and resonance peak
waveforms of a healthy tissue.
[0034] FIGS. 11 and 12 are respective signal and spectrum waveforms
of an abnormal tissue.
[0035] FIGS. 13 and 14 are respective signal and EMR peak for
spectra diagrams showing the treatment wave superimposed upon the
waveform to be treated.
DETAILED DESCRIPTION OF THE INVENTION
[0036] With reference to the general block diagram view of FIG. 1,
my inventive system for analyzing and treating abnormality of human
and animal tissues may be seen to include a functional management
unit ("FMU") 100 which supervises functions of a communication
module 102, a stimuli module 104, and a measurement module 106.
[0037] As may be noted in FIG. 2, the primary hardware of the
inventive system is associated with a patient treatment unit
("PTU") 108 which includes said measurement module 106 and stimuli
module 104. The stimuli module functions through probes or
induction coils 110/111 thru which the initial data required by
measurement module 106 is captured. In FIG. 2 may also been seen
the physical relationship between a PC 112 and a diagnostic unit
114 which includes said communication module 102. Diagnostic unit
114 and PC 112 comprise integral components of said FMU 100.
Further shown in FIG. 2 are pads 116 which facilitate treatment of
patient 118 by an operator 120. Line 122 represents a human and
animal interface between patient 118 and operator 120 while line
124 represents a radio interface means between the PC and
diagnostic unit, 114 on the one hand, and the PTU 108 on the other.
Structural and parametric heuristic control of diagnostic unit 114
and PTU 108 are indicated by line 126 of FIG. 2.
[0038] The electrical output specifications of PTU 108 are as
follows:
TABLE-US-00001 Power Supply 115 VAC, 60 Hz Maximum Power
Consumption 21 W Output voltage Range of normal use: 50-60 V Peak
pulse amplitude: 120 V Pulse Rate 1-490 Pulses/second, .+-.6% Pulse
Duration 0.34-0.74 millisecond Output Current (maximum) 8.9
milliamps Maximum charge per pulse 7 micro coulombs Wave Form
Complex pulse trains: variable frequency, variable pulse width,
AC-coupled rectangular pulse
[0039] In FIG. 3 is shown FMU 100, inclusive of stimuli-measurement
timing control means 128, radio interface control 130, local handle
treatment control inputs 132 which are associated with said pads
116, a PTU display management facility 134 associated with said
diagnostic unit 114, and a battery status monitor 136.
[0040] In FIG. 4 is schematically shown the use of custom software
running upon said PC 112 to control the PTU 108 and manage a
patient list. Said PC is connected to a PTU 108 through said radio
interface 124.
[0041] In FIG. 5 is shown measurement module 106 which includes
means 138 for measurements of the surface impedance of a treated
tissue and means 140 for measurement of the impedance of the tissue
to be treated.
[0042] Output waveforms of PTU 108, showing various impedance,
power, and frequency relationships are shown in FIGS. 5A-5D. More
particularly, FIG. 5A indicates a 1M-Ohm maximum impedance, in
which the output waveform varies depending on the load as shown in
FIGS. 5B-5D. That is, FIG. 5B shows voltage versus time at 500
ohms. FIG. 5C shows voltage versus time at 5000 ohms, and FIG. 5D
shows voltage versus time at 10,000 ohms. Therein, changes in load
affect both pulse duration and maximum pulse frequency. Maximum
pulse frequency lies in a range of 490.+-.6% from 500 ohms to
1,000,000 ohms. Lower impedances have lower maximum pulse rates.
Pulse width is fixed at a given impedance, and declines from 0.74
milliseconds at 500 ohms to 0.34 milliseconds at 1,000,000
ohms.
[0043] In FIG. 6 is shown communication module 102 and its
important internal functions which include subsystem 142 which
indicates the receipt and resending of error check stimuli
information from a local controller (LC) which includes battery
status information 144 and electrode or induction coil status
information 146. Communication module 102 also includes subsystem
148 which sends, receives and error checks measurements of both
surface and tissue as above described with reference to FIG. 5.
Therein the skin-electrode or induction coil and tissue electrode
or induction coil impedance is continually monitored at the LC in
visual and/or audio terms to thereby enable the medical technician
to adjust the pressure of the electrodes or the medium (such as
electro-jelly) used between the electrode and the treated
tissue.
[0044] In FIG. 7 are shown the primary constituent subsystems of
the PTU 108, these including a microcontroller 149 having a said
local treatment controls 132, said display 134, status LEDs 135, a
memory 150 used for purposes of recording data, and a DC to DC
converter 152. As may be noted, the output of converter 152 feeds
into pulse generator and level shifting means 154 which include
current and voltage limiting means. The output of said means 154 is
provided to means 156 for the simultaneous sensing of voltage and
current associated with skin and tissue measurements. The output
thereof is provided to said microcontroller 149 which operates with
PC 112 through radio interface unit 124. The PTU 108 also includes
a battery pack 158 and its charger 160.
[0045] Inputs to probes or induction coils 110 and 111 are provided
through said dual voltage and current sensing means 156. It is
noted that there are two areas in which magnetic resonance
fluxuation is measured. The first is through an induction coil and
the second is through the treatment measurement probes. The more
phase shift (disorder or electrons loss of energy etc) the lower
the measured amplitude and the greater the electromagnetic
fluxuation.
[0046] In FIG. 8 is shown stimuli module 104 and, more
particularly, over voltage and over-current software monitoring
means 162, associated electrode or induction coil monitoring means
164, and associated RI means 166 for processing data received from
radio interface unit 124, and means 168 for processing data from
local treatment controls 132.
[0047] It is to be appreciated that electrodes associated with
probes 110/111 and pad 116, that is two electrodes connected via
wire, one of which electrodes is provide with a linear
potentiometer are used to adjust or select the intensity of the
energy provided to the treated tissue. A number of safety features
are incorporated into the instant system including visual and/or
audio warning means, amplitude limit means (per block 156),
amplitude override means, amplitude ramp back means, and patient
control means. Therein data transmitted from functional management
unit 100 to the PTU 108 includes stimuli frequency, stimuli duty
cycle, and patient pain threshold information (based upon patient
history) to thereby optimize PTU-side intensity settings. Data
transmitted between the PTU and FMU include skin voltage,
electromagnetic fluxuation and current (see FIG. 5), phase between
skin and voltage current, tissue voltage and current, phase between
tissue voltage, electromagnetic fluxuation and current, and
stimulus on/off status (see FIG. 3).
[0048] Importantly, the local controller (see FIG. 4) of the
present EMR system employs various algorithms.
[0049] Perhaps most importantly, the LC of the EMR system employs
various algorithms, starting with a so called inverse wave form of
the injury tissue as a first order basis of treatment, this to be
followed by robust stochastic models to generate appropriate
stimuli profiles to enable the FMU 100 to provide a sophisticated
treatment or correction signal. Therein at least three models or
algorithms are contemplated, these including the following: [0050]
sequential, adaptive self-learning method and implementation (for a
single electrode pair); [0051] block adaptive self-learning method
and implementation (for an electrode array); [0052] one and multi
dimensional neural network-based controller algorithms; [0053]
sequential data autoregressive method and implementation (for a
single electrode pair); and [0054] block data autoregressive method
and implementation (for an electrode array)
[0055] In addition, the filtering of the measurement module of the
FMU eliminates error signals which typically appear as waveform
ripples, to thereby enable generation of a correction or treatment
signal from a self-learning multi-electrode PTU, thereby having
enhanced efficacy in the cancellation of pain and, ultimately, long
term treatment of the condition of interest.
[0056] Combinations of algorithms may be employed to generate
interchannel waveform correlations to ensure convergence of the
model analysis and promotion of its learning curve for the modeling
of the tissue injury, treatment profiles and peak resonances
associated therewith.
[0057] In summary, the technology employ a frequency of 1 Hertz to
1G hertz, and low gauss (0.1 to 4 Tesla) in treatment signals to
increase, decrease, flatten or nullify out of phase resonance peaks
of a measured waveform of the tissue to be treated. Similarly, the
correction or treatment signal which is applied to treat the
abnormal tissue signal obtained by the measurement module is
intelligently developed by a self-learning multi-electrode PTU in
which various heuristic algorithms are used to ensure convergence
and efficient development of models necessary to optimize tissue
profile, peak resonance codes, and the use of this information for
effective therapy in an array of medical conditions.
[0058] This technology also enables treatment of conditions such as
arthritis, post surgical pain, post surgical reduction of swelling
inflammation and bruising, Osgood Schlater Disease, treatment of
organ transplant patients for the purpose of reducing organ
rejection, adhesive capsilitus, MS, ALS, motor neuron disease,
reduction of keloid scaring treatment of skin graft sites for
better vasculasation and better chance of successful graft
improvement of circulation and oxygen saturation in compromised
tissue and limbs, limb and digit reattachment for better chance of
successful graft, improvement and normalization of conductivity in
infarcted cardiac tissue, joint inflammation and injuries,
fibromyglia, reflex sympathetic dystrophy, neuralgia, peripheral
neuropathy, macular degeneration, wounds and sclerdemia. However, a
library of tissue profiles and peak resonance codes may be employed
in the system in the development of a separate library of profiles
and EMR resonance codes for each patient and, also, as a
baseline/or electromagnetic structures, of healthy tissue of many
types, which might be employed in the generation of an inverse
waveform (see discussion in FIGS. 13-14 below) or treatment
purposes. Accordingly, my historic library of tissue profiles and
peak resonance codes may be intergraded into the stochastic models,
as set forth above, to generate appropriate stimuli profiles to
enable a sophisticated treatment or correction signal. Therein a
simple low-order low pass filtering process, to eliminate signal
ripples, constitutes a starting point.
[0059] The next step is typically the generation of the inverse
waveform or inverse EMR spectra which is a generation of an
opposite magnetic single pattern from that shown in FIGS. 11 and
12. The application of this inverse pattern, has a pulse width
modulation (PWM) process imposed upon a "sick" signal of the
abnormal tissue is shown in FIG. 13. Thereby the system generates
and applies to such tissue, a waveform of EMR peak spectra
substantially inverse to that of out-of-phase resonances of said
tissue signal to thereby increase or nullify EMR peaks of the
signal associated with abnormalities. See FIG. 14.
[0060] While there has been shown and described the preferred
embodiment of the instant invention it is to be appreciated that
the invention may be embodied otherwise than is herein specifically
shown and described and that, within said embodiment, certain
changes may be made in the form and arrangement of the parts
without departing from the underlying ideas or principles of this
invention as set forth in the Claims appended herewith.
* * * * *